BioNexus Gene Lab Total Liabilities 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab total liabilities from 2019 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

BioNexus Gene Lab Total Liabilities 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab total liabilities from 2019 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$91.4B
Cencora (COR)	$47.5B
DiDi Global (DIDIY)	$23.3B
Natera (NTRA)	$21.4B
ICON (ICLR)	$16.1B
Viatris (VTRS)	$15.6B
Avantor (AVTR)	$13.4B
Revvity (RVTY)	$13.4B
CochLear (CHEOY)	$12.8B
BioMerieux (BMXMF)	$12.7B
Solventum (SOLV)	$11.6B
Medpace Holdings (MEDP)	$9.8B
Doximity (DOCS)	$9.6B
Charles River Laboratories (CRL)	$9.5B
HealthEquity (HQY)	$9B
Sonic Healthcare (SKHHY)	$8.8B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Sotera Health (SHC)	$3.9B
Organon (OGN)	$3.8B
BrightSpring Health Services (BTSG)	$3.2B
Surgery Partners (SGRY)	$2.9B
PACS (PACS)	$2.6B
Concentras Parent (CON)	$2.6B
Ardent Health Partners (ARDT)	$2.4B
Premier (PINC)	$2.1B
Alignment Healthcare (ALHC)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GeneDx Holdings (WGS)	$2B
GoodRx Holdings (GDRX)	$1.6B